03 May New Immunotherapy Supplier for High-Risk Neuroblastoma
A New European supplier of Dinutximab Beta has been confirmed, ensuring the ongoing provision of fully-funded, standard of care immunotherapy for high-risk neuroblastoma.
Click here for a full update.